Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

Circulating cell‐free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial liquid biopsies to enable tumor genome analysis throughout the course of treatment. We investigated cfDNA and mutant ctDNA as potential biomarkers to predict the best outcomes of regorafenib‐t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pastor, Brice, André, Thierry, Henriques, Julie, Trouilloud, Isabelle, Tournigand, Christophe, Jary, Marine, Mazard, Thibault, Louvet, Christophe, Azan, Simon, Bauer, Audrey, Roch, Benoit, Sanchez, Cynthia, Vernerey, Dewi, Thierry, Alain R., Adenis, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410523/
https://www.ncbi.nlm.nih.gov/pubmed/33934494
http://dx.doi.org/10.1002/1878-0261.12972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410523/
https://www.ncbi.nlm.nih.gov/pubmed/33934494
http://dx.doi.org/10.1002/1878-0261.12972

Ejemplares similares